2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMOCompleted
To provide proof of concept that POWER2DM is safe and effective in improving glycaemic control and analyse of the cost-effectiveness of the approach to highlight any potential issues that may impede implementation.